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Abstract  Article Information 
Improving oral bioavailability of drugs those given as solid dosage forms remains a 
challenge for the formulation scientists due to solubility problems. The dissolution rate 
could be the rate-limiting process in the absorption of a drug from a solid dosage form of 
relatively insoluble drugs. Therefore increase in dissolution of poorly soluble drugs by 
solid dispersion technique presents a challenge to the formulation scientists. In the 
present work solid dispersed drug was prepared by Fusion technique as a novel system 
for enhancing the delivery of piroxicam, a non-steroidal anti-inflammatory drug. This solid 
dispersed drug was prepared from polyvinyl pyrrolidone (PVP) (pharmaceutical grade), a 
biodegradable polymer, to obtain a solution with drug: polymer ratio of 1:5. The release 
rate of the piroxicam solid dispersed drug was studied in simulated gastric fluid. Fourier 
transform infrared (FTIR) and scanning electron microscopy (SEM) are used to evaluate 
the chemical and physical nature. The results showed that the release rates were twice 
increased in comparison with the pure drug. However, the blend of drug and polymer 
could be varied to optimize the release rates depending upon the need and formulation.  
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INTRODUCTION 
Oral bioavailability of drugs depends on its solubility 
and/or dissolution rate, the major problem associated with 
poorly-water soluble drugs was its very low solubility in 
biological fluids, which results into poor bioavailability after 
oral administration (Sekiguchi, and Obi, 1961; Leunner, 
and Dressman, 2000). A drug with poor aqueous solubility 
will typically exhibit dissolution rate limited absorption, and 
a drug with poor membrane permeability will typically 
exhibit permeation rate limited absorption (Goldberg et al., 
1966). Therefore, pharmaceutical researchers' focuses on 
two areas for improving the oral bioavailability of drugs 
include: (i) enhancing solubility and dissolution rate of 
poorly water-soluble drugs and (ii) enhancing permeability 
of poorly permeable drugs (Amidon et al., 1995). 
 
Piroxicam is a member of the oxicam group of non-
steroidal anti-inflammatory drugs (NSAIDs). The chemical 
name for piroxicam is 4-hydroxyl-2-methyl-N-2-pyridinyl-2 
H-1, 2- benzothiazine-3-carboxamide 1,1-dioxide. It is 
indicated for acute or long-term use in the relief of signs 
and symptoms of osteoarthritis and rheumatoid arthritis 
(Physicians’ Desk reference, 56
th
 ed, 2002). According to 
the Biopharmaceutic Drug Classification System (BCS) 
(Amidon et al., 1995) piroxicam is a class 2 drug, 
characterized by low solubility-high permeability. Drug 
dissolution in vivo is the rate-controlling step in drug 
absorption. Several techniques have been used to 
improve the oral bioavailability of piroxicam by 
accelerating its dissolution rate. These mainly include the 
solid dispersion techniques based on cyclodextrin 
inclusion complexes (Reddy and udupa 1993; Cavallari et 
al., 2002), polyvinyl pyrrolidone (Tantishaiyakul et al., 
1999), polyethylene glycols 4000 and 6000 
(Bhattacharyya et al., 1993; Fernandez et al., 1992). 
 
Solid dispersions technique have tremendous potential 
for improving drug solubility due to the following factors 
(Leuner and Dressman, 2000; Damian et al., 2000; 
Govindasamy et al., 2013): a reduction of drug’s particle 
size to nearly a molecular level, a solubilising or a 
cosolvent effect on the drug by the water soluble carrier, 
better wettability and dispersibility of the drug by the 
carrier material, and the formation of amorphous forms of 
drug and carriers. Polymerization of vinyl pyrrolidone 
leads to polyvinyl pyrrolidone (PVP) of molecular weights 
ranging from 2500 to 3,000,000. These can be classified 
according to the K value (Walking 1994). Due to their 
good solubility in a wide variety of organic solvents, they 
are particularly suitable for the preparation of solid 
dispersions by the solvent method. Similarly to the PEGs, 
PVPs have good water solubility and can improve the 
wettability of the dispersed compound in many cases. 
Improved wetting and thereby an improved dissolution 
rate from a solid dispersion in PVP has been 
demonstrated for flufenamic acid (Aso et al., 2009). The 
chain length of the PVP has a very significant influence on 
the dissolution rate of the dispersed drug from the solid 
dispersion. The aqueous solubility of the PVPs becomes 
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PVP as excipients has been studied extensively for 
increasing solubility and enhancing intestinal permeability 
and oral bioavailability of poorly water soluble drugs 
(Damian et al., 2000; Itoh et al., 2002). The present study 
was designed to improve the dissolution rate of piroxicam 
at the physiological pH’s through its increased solubility by 
preparing semi-solid dispersions of the drug with polyvinyl 
pyrrolidone (PVP). The effect of PVP as excipients on the 
solubility and dissolution rate of piroxicam was evaluated. 
FTIR analysis between drug and polymer was performed 
to investigate possible interactions between drug and 
excipients. 
 
MATERIALS AND METHODS 
Materials 
Piroxicam (≥98.0%), Polyvinyl Pyrrolidine (PVP) 
(Mw=13, 00,000) and Dialysis tubing cellulose membrane 
have been purchased from Sigma–Aldrich, Bangalore, 
India. Ethanol, Monobasic sodium phosphate (NaH2PO4) 
and dibasic sodium phosphate (Na2HPO4) were 
purchased from Emplura
®
, Merck Specialities Private 
Limited, Bangalore, India. 
 
Preparation of Piroxicam Based Solid Dispersed Drug 
Piroxicam based solid dispersed drug was prepared by 
Fusion/ Melt technique (Sekiguchi, and Obi, 1961). 150 
mg Piroxicam drug was dissolved in 10 ml of 0.75% of 
PVP polymer containing heated ethanol by continuous 
stirring, giving the drug and polymer concentration ratio of 
1: 5 (Piroxicam : PVP). After complete dissolving of 
Piroxicam drug, drug polymer solution was transferred to 
the mortar and allowed it to cool under room temperature. 
After complete cooling and solidification of drug polymer 
solution in mortar it was finely churned to powder by using 
passel giving Piroxicam based PVP solid dispersed drug. 
 
Characterization of Solid Dispersed Drug 
SEM Analysis 
The external surface morphology and diameter of 
Piroxicam based PVP solid dispersed drug were studied 
by SEM. The solid dispersed drug was observed under a 
scanning electron microscope (FEI Quanta 200, Indian 
Institute of Science, Bangalore). They were mounted 
directly on to the SEM sample stub using double-sided 
sticking tape and coated with gold film (thickness 200 nm) 
under reduced pressure (10
-4
mm of Hg). 
 
FTIR Analysis 
The procedure involving sample preparation and 
spectral recordings was carried out by previously 
described method (Stuart et al., 2004). IR spectra of 
Piroxicam, PVP and PVP solid dispersed drug  were 
recorded using FTIR Nicolet 6700 (Thermo Fisher 
Scientific, Madisson, WI, USA) operated by Omnic 
software 8.1. In particular, for oral thin films measurement 
the spectra were obtained by attenuated total reflectance 
(ATR) method using smart orbit diamond ATR. Briefly, the 
formulations were placed individually on the sample plate 
of the smart orbit and screwed lightly to record IR spectra 
in ATR mode. 
 
In vitro Dissolution Studies  
Construction of Calibration Curve  
Piroxicam can be estimated spectrophotometrically at 
λmax 330 nm. 100 mg of piroxicam was dissolved in 0.1 N 
methanolic HCl to obtain a solution with the piroxicam 
concentration of 100µg ml
-1
. Serial dilutions containing 2, 
4, 6, 8, 10 µg ml
-1
 of piroxicam were prepared with the 
same solvent. Absorbance of each solution was 
measured at 333 nm. A plot of concentrations of drug 




Figure 1: Calibration curve for the estimation of piroxicam 
in 0.1N methanolic Hcl at 333nm. 
 
Estimation of Piroxicam Concentration  
Piroxicam based PVP solid dispersed drug equivalent 
to 20 mg of piroxicam were weighed and dissolved in 0.1 
N methanolic HCl and the absorbance was measured at 
333 nm.  
 
In vitro Release Behavior of Piroxicam 
The in vitro dissolution studies were done to compare 
the rate of dissolution of these prepared Piroxicam based 
PVP solid dispersed drug with that of the pure drug. The 
test was performed in the United States Pharmacopeia 
Convention USP paddle apparatus using 900 ml of 0.1 N 
HCl (pH 1.2) at 37±0.5
0
C and 50 rpm. Aquilots of 5 ml 
were withdrawn at various time intervals of 5, 10, 20, 30 
and 60 min and analyzed by UV spectrophotometer 
(Evolution 300; Thermo Fisher Scientific, Madisson, WI, 
USA) at 333 nm. 
 
RESULTS AND DISCUSSION 
Physico-Chemical Characterization 
SEM Analysis 
The solid dispersed drug was observed under a 
scanning electron microscope (FEI Quanta 200, Indian 
Institute of Science, Bangalore). Solid dispersed drug 
obtained was with average diameter of about 3600 nm 
(Image J software, provided by National Institutes of 
Health, USA). Piroxicam solid dispersed drug was 
detected by electron microscopy, indicating uniform 
distribution of drug and polymer solution (Figure-2a & 2b). 
The Piroxicam-PVP loaded solid dispersed drug diameter 
is large and can be decreased by further optimizing the 
parameters used for the fusion/melt process.  
 
FTIR Analysis 
IR spectra of piroxicam and Polyviny pyrrolidone were 
shows the prominent peeks for functional group like N-H, 
C-H (aliphatic and aromatic), C=O, C-O, C-N, C-F and 
S=O. When comparing the solid dispersed piroxicam with 
Polyviny pyrrolidone, have found no interaction of 
piroxicam with Polyviny pyrrolidone, which are confirmed 
with the prominent peeks of functional groups and does 
not show any additional peeks for other functional groups 
(Figure 3 and Table 1). 
























Figure 2: SEM images of Piroxicam-PVP solid dispersed drug a) Lower magnification b) Higher magnification. 
 
 
Figure 3: FTIR spectra of Piroxicam, PVP and Piroxicam solid dispersion with PVP. 
 




Wave number (cm−1) 
Piroxicam 
Piroxicam:  
PVP solid dispersed drug 
N-H (stretch) 3333.88 3394.72 
C-H(stretch) 3010.2 2952.14 
C=O 1627.78 1643.91 
C-O 1214.64 1287.84 
C=C 1433.12 1461.20 
C-N 1347.24 1373.06 
S=O 1038.37 1050.02 
C-F  1422.22 
 
In vitro Dissolution Studies 
The rate of piroxicam released from Piroxicam based 
PVP solid dispersed drug was studied at pH 1.2 and at 
temperature of 37±0.5
◦
C. The rate of release of piroxicam 
from solid drug is governed by temperature, nature of the 
used polymer and pH of the used simulated fluid. The 
solid dispersion technique is newly utilized in the field of 
drug delivery. It provides a unique and simple technique 
for improving drug delivery. The advantages of this 
technique are that it could be applied for a wide range of 
pharmaceutical compounds depending upon their nature. 
It could be applied for a mixture of drugs at the same time; 
besides, polymer blends could be used as solid dispersed 
drug at the same time. Also, it is possible to mix different 
polymeric drug molecules as layers which will help in 
layer-by-layer assembly to enhance the dissolution rate. 
The release rate of piroxicam based PVP solid dispersed 
drug showed a relatively higher rate than that of pure drug 
(Table 2 and Figure 4). After 60 min of dissolution time 
there is a marked increase in dissolution rate from 71.47 ± 
0.81 to 94.32 ± 0.59 which clearly indicates that around 
91% of the drug concentration is available with solid 
dispersed drug and only 63% for pure drug. 
a b 
 





Figure 4: Comparative dissolution profile of Solid 
dispersed Drug and pure drug in 0.1N HCl. 
 
Table 2: Comparative dissolution profile of Solid 
dispersed Drug and pure drug at pH 1.2. 
 
 
Time (min) Cumulative % of drug dissolved 
 Piroxicam pure 
drug 
Piroxixam: PVP (1:5) 
solid dispersed drug 
5 16.12 ± 0.33 33.58 ± 0.46 
10 35.17 ± 0.72 58.81 ± 0.72 
20 57.63 ± 0.87 81.15 ± 0.53 
30 65.16 ± 0.53 90.22 ± 0.92 
60 71.47 ± 0.81 94.32 ± 0.59 
 
CONCLUSION 
In the present study PVP was employed in the 
preparation of solid dispersed drug, as it acts as a 
hydrophilic carrier, thereby enhancing the dissolution rate 
of the drug. The release rate of Piroxicam-PVP solid 
dispersed drug dissolution was twice increased as 
compared with the pure drug. SEM analysis indicated the 
average diameter of PVP solid dispersed drug (3600 nm). 
FTIR spectra indicated the absence of drug–polymer 
interactions. A new drug delivery system for piroxicam, a 
non-steroidal anti-inflammatory drug (NSAID), was 
developed. These systems were based on fusion 
method/melt method of piroxicam with a suitable polymer. 
PVP polymer is biodegradable and biocompatible. Further 
research will be focused on optimization of parameters 
like pH, temperature and drug: polymer ratio etc to control 
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